



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

May 30, 2024

John Sperzel  
President, Chief Executive Officer and Chairman of the Board  
T2 Biosystems, Inc.  
101 Hartwell Avenue  
Lexington, MA 02421

**Re: T2 Biosystems, Inc.**  
**Registration Statement on Form S-3**  
**Filed May 28, 2024**  
**File No. 333-279740**

Dear John Sperzel:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Conlon Danberg at 202-551-4466 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Industrial Applications and  
Services

cc: Johan Brigham, Esq.